

ESOI Touchdown 2026 Heidelberg

October 29-31, 2026

Heidelberg, Germany

We are proud to present this year's ESOI Touchdown programme, bringing the European oncologic imaging community together in Heidelberg from October 29-31 for three days of intensive, high-level education. The schedule is packed with diverse formats, including high-level scientific sessions on cutting-edge oncologic diagnostics, hands-on interactive workshops covering specific anatomical challenges, and live multidisciplinary team sessions.

Please note the programme might still be subject to modifications and might not be the final version.

Thursday, October 29, 2026

08:30-08:45	Welcome and Opening- Touching down at the Frontiers of Oncology with Advanced Imaging Moderators: M. D'Anastasi, Malta/MT, H.-P. Schlemmer, Heidelberg/DE
08:45-09:45	Signal to Decision: How AI Is Transforming Radiology into the Engine of Integrated Oncologic Diagnostics Moderators: E. Neri, Pisa/IT, S. Schönberg, Mannheim/DE
08:45-09:00	One Dashboard to Rule Them All: The AI-Powered Hub for Integrative Diagnostics M. Frölich, Hamburg/DE
09:00-09:15	Beyond the Image: The Digital Twin as Co-Pilot for Early Detection and Personalized Medicine M. Görtz, Heidelberg/DE
09:15-09:30	AI-enhanced Pathway Optimization & Clinical Benchmarking across the Full Prostate Cancer Diagnostic-to-Therapeutic Chain D. Nörenberg, Mannheim/DE
09:30-09:45	Beyond Static Analysis: Agentic AI Systems in Radiology for Optimized Disease Management M. Klontzas, Heraklion/GR
09:45-10:15	Coffee Break ☕

10:15-11:15	Lung Cancer MDT
Our programme features a collaborative deep dive into lung oncology, bringing together a panel of specialists to discuss complex cases from every angle. You will gain insights from a diverse range of experts, including Thoracic surgery, Pneumology, Pathology and Nuclear medicine	
	C.-P. Heußel, Heidelberg/DE R. Shah, Heidelberg/DE
11:15-11:25	Break 🕒
11:25-12:15	Industry Sponsored Symposium Advancing Precision Oncology with Spectral CT D. Caruso, Rome/IT
12:15-13:00	(Lunch) Break 🍽️
13:00-13:20	Keynote Lecture Moderator: H.P. Schlemmer, Heidelberg/DE Individualising Oncologic Diagnostics: The Transformative Power of Liquid Biopsy K. Heinrich, Munich/DE
13:20-13:30	Break 🕒
13:30-14:45	Cancer of Unknown Primary- Imaging at the Diagnostic Frontier Moderators: W. Kunz, Munich/DE, A. Laghi, Rome/IT
13:30-13:45	Radiologist's Approach to Cancer of Unknown Primary: Key Imaging Findings and Diagnostic Algorithms C. Kelly-Morland, London/UK
13:45-14:00	The emerging role of MRI in Cancer of Unknown Primary M. Lahaye, Amsterdam/NL
14:00-14:15	Cancer of Unknown Primary: Case-Based Imaging Pearls and Pitfalls D. Lambregts, Amsterdam/NL

14:15-14:30 **Nuclear Imaging in Cancer of Unknown Primary: Current Role and Future Directions**
C. Cyran, Munich/DE

14:30-14:45 **Discussion**

14:45-15:15 Coffee Break ☕ & Poster Walking Tour

15:15-16:00 Interactive Workshops

Highly interactive environment in smaller groups with live discussion. Participants are free to decide which workshop to attend.

Workshop 1: MRI Characterization of Ovarian Masses (Auditorium)

L. Fournier, Paris/FR

E. Vasiliu, Bucharest/RO

Workshop 2: Bone Metastasis & Their Mimics (Room K1)

S. Gitto, Milan/IT

S. Kaur, Oswestry/UK

Workshop 3: Imaging in Hematologic Malignancies (Room K2)

D. Leithner, New York/US

M. Mayerhöfer, New York/US

Workshop 4: Patient Communication for Radiologists (Foyer)

D. Carrié, Toulouse/FR

M. Zerunian, Rome/IT

**Workshop EUCAIM: The Cancer Image Europe Infrastructure:
Leveraging Cancer Imaging Data for Research and Innovation**

S. Flor, Valencia/ES

H. Leisz, Heidelberg/DE

18:00-20:00 Keynote Address "The Evolution and Importance of Oncologic Imaging"

L. Marti-Bonmati, Valencia/ES

Venue: Alte Aula University Building

Friday, October 30, 2026

08:30-09:15 Interactive Workshops

Highly interactive environment in smaller groups with live discussion. Participants are free to decide which workshop to attend.

Workshop 5: Primary Liver Malignancies: Imaging for Detection and Treatment (Auditorium)

S. Kale, Bengaluru/IN

M. Radziņa, Riga/LV

G. Zamboni, Verona/IT

Workshop 6: Challenges in Head & Neck Imaging (Room K1)

E. Vassallo, Msida/MT

A. Venkatasamy, Paris/FR

Workshop 7: Prostate Cancer: From PI-RADS to Individualized Care (Room K2)

T. Boellaard, Amsterdam/NL

G. Cappello, Turin/IT

Workshop 8: Communication of Scientific Results: How to present yourself (Foyer)

A. Borgheresi, Ancona/IT

G. Sargsyan, Yerevan/AM

09:15-09:25 Break

09:25-10:25 **Stop Writing Novels: The Future of Radiology Reporting**

Moderators: H.-C. Becker, Stanford/US, C. Cyran, Munich/DE, M. D'Anastasi, Msida/MT

09:25-09:40 **Structured Reporting: Salvation or Straightjacket?**

S. Fanni, Pisa/IT

09:40-09:55 **The Report Writes Itself: Are Radiologists Becoming Editors**

L. Müller, Mainz/DE

09:55-10:10 **Dear Radiologist: This Is Not The Report We Need**

D. Apostolidis, Heidelberg/DE

10:10-10:25 **Panel Discussion - The Radiology Report of 2035**

10:25-10:45 Coffee Break

10:45-11:45	Bridging Science and Care: Partnership of Patients, Clinicians and Scientists Moderators: D. Carrié, Toulouse/FR, M. Reiser, Munich/DE
10:45-11:00	Artificial Intelligence & Emotional Intelligence- The perfect match for good? C. Justich, Vienna/AT
11:00-11:15	Patients as Partners: A clinician scientist's and oncologist's perspective G. Ungerechts, Heidelberg/DE
11:15-11:30	Improving Clinical Studies Through Patient-Centred Engagement: A Psycho-Oncological Perspective T. Bugaj, Heidelberg/DE
11:30-11:45	Panel Discussion
11:45-11:55	Break 🕒
11:55-12:45	Industry Sponsored Symposium: Photon-counting CT in Oncology: From Clinical Impact to Interactive Reading
11:55-12:15	Photon-counting CT in Oncology L. Thomas Rotkopf, Heidelberg/DE
12:15-12:35	Interactive photon-counting CT spectral image reading C. Booz, Frankfurt/DE
12:35-12:45	Questions & Answers V. Kneißl, D. Stromer, Germany
12:45-13:30	(Lunch) Break 🍽️
13:30-14:30	Urogenital Cancer MDT This session offers a comprehensive look at the patient journey through a coordinated multidisciplinary approach. Experts will discuss the latest strategies in diagnosis and treatment, providing perspectives from Urology, Radiology, Pathology and Oncology. D. Bonekamp, Heidelberg/DE V. Schütz, Heidelberg/DE C. Schwab, Heidelberg/DE S. Zschäbitz, Heidelberg/DE
14:30-14:40	Break 🕒

14:40-15:40 Scientific Session 1: Therapy Monitoring (Auditorium)

Moderators: H.P. Schlemmer, Heidelberg/DE, G. Avesani, Rome/IT

Don't miss key insights from our colleagues on Therapy Monitoring. Dive into the latest research and discover new updates in the field. A syllabus of all presented abstracts will be available through the ESOI website.

14:40-14:45 Definition of MRI complete response in multiple myeloma focal lesions- a lesion-based comparison with 18F-FDG PET/CT from the GMMG-HD7 imaging sub-study

M. Wennman, Heidelberg/DE

14:45-14:50 CEUS with VEGFR2-targeted microbubbles for monitoring of early immunotherapy effects in a colorectal cancer model

F. Herr, Munich/DE

14:50-14:55 Hybrid SSTR-PET/ CT criteria outperform RECIST 1.1 or SSTR-PET criteria alone in GEP-NET undergoing PRRT

F. Herr, Munich/DE

14:55-15:00 Superior Overall Survival Prediction with RECIST 1.1 Compared to Choi and Volumetric Response Criteria in PRRT-Treated GEP-NET

F. Herr, Munich/DE

15:00-15:05 Use of the Metro-Pancreas algorithm to reduce futile resections in Patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment

I. Panozzo, Verona/IT

15:05-15:10 MRI Evaluation of the Local Response of Pancreatic Ductal Adenocarcinoma Before and After Neoadjuvant NALIRIFOX Therapy

I. Panozzo, Verona/IT

15:10-15:15 Automating oncological response evaluation with a promptable tumor-tracking foundation model

J. Holzschuh, Heidelberg/DE

15:15-15:20 Opportunistic AI-Based Baseline Body Composition from RoutineCT predicts PFS in Pancreatic but Not small Neuroendocrine Tumors Under Somatostatin Analogs

M. Fauter, Munich/DE

15:20-15:25 **Dixon MRI Evaluation of Neoadjuvant Therapy- Related Hepatic Toxicity and Steatosis in Patients with Pancreatic Ductal Adenocarcinoma**

A. Fattorini, Verona/IT

15:25-15:30 **LI-RADS CT/MRI Radiation Treatment Response Assessment Version 2024: Performance and category redistribution compared to Treatment Response Assessment Version 2018**

S. Sadananda, Bangalore/IN

15:30-15:40 **Discussion**

14:40-15:40 **Scientific Session 2: Diagnosis and Staging (Room K1)**

Moderators: F. Gallagher, Cambridge/UK, D. Leithner, New York/US

Don't miss key insights from our colleagues on Diagnosis and Staging. Dive into the latest research and discover new updates in the field. A syllabus of all presented abstracts will be available through the ESOI website.

14:40-14:45 **Cross-sectional imaging of pancreatic squamous cell carcinoma: comparison with size-matched pancreatic ductal adenocarcinoma**

F. Omboni, Verona/IT

14:45-14:50 **Diagnostic Accuracy Of Multiparametric MRI Breast in Differentiating Benign And Malignant Non Mass Enhancement Breast Lesions**

S. Sadananda, Bangalore/IN

14:50-14:55 **Assessment of lymph node metastases by Node-RADS: a Systematic review and meta-analysis on its diagnostic accuracy in the context of abdominal and pelvic malignancies**

M. Bensalah-Faria, Fribourg/CH

14:55-15:00 **Reproducibility of O-RADS MRI Dynamic Contrast-Enhanced Curve assessment in indeterminate Adnexal Masses**

L. Hoxha, Bolzano/IT

15:00-15:05 **MRI-US Fusion-Guided Second-Look Ultrasound in Breast Imaging: A Prospective Study**

L. Lusiani, Turin/IT

15:05-15:10	Beyond Peritoneal Cancer Index: Incremental Value of Diffusion-Weighted MRI Over CT for Predicting Complete Cytoreduction J. Goyal, New Delhi/IN
15:10-15:15	AI-Derived Zonal PSAD and Tumor-Derived MRI Parameters for the Prediction of Clinically Significant Prostate Cancer A. Alicioglu, Zonguldak/TR
15:15-15:20	Scan-related anxiety and correlation with image quality in whole-body MR-imaging in individuals with Li-Fraumeni syndrome S. S. Bruns, Hannover/DE
15:20-15:25	A screening roadmap drawn without radiologists? Concordance of IMACS myositis recommendations with population-based imaging guidelines I. Capitoni, Siena/IT
15:25-15:30	Optimizing Virtual Non-Calcium Maps for Multiple Myeloma Bone Lesion Detection: A Quantitative and Qualitative Analysis of Calcium Suppression Indices D. Costanzo, Torino/IT
15:30-15:40	Discussion
14:40-15:40	Scientific Session 3: Advances in Oncological CT (Room K2) Moderators: H.-C. Becker, Stanford/US, P. Bonaffini, Bergamo/IT Don't miss key insights from our colleagues on Advances in Oncological CT. Dive into the latest research and discover new updates in the field. A syllabus of all presented abstracts will be available through the ESOI website.
14:40-14:45	Less is More: Dual-Energy CT and Contrast Reduction in Oncologic Follow-Up I. Capitoni, Siena/IT
14:45-14:50	The Clinical Impact of PET/CT on Patient Selection for Stereoactive Body Radiotherapy: A Retrospective Cohort Study B. Luo, London/UK
14:50-14:55	Prognostic Value of CT-Derived Features for Five-Year Overall Survival in Locally Advanced Colon Cancer: A Multi-Reader Study J. Shkurti, Amsterdam/NL

14:55-15:00	Integrating CT-Derived Anthropometric Biomarkers into the MetroPancreas Score for Predicting Futility in Upfront PDAC Surgery E. Danzo, Verona/IT
15:00-15:05	CT-Based Radiomics Machine Learning Model to Predict Response to Lu-177 DOTATATE in Advanced Gastroenteropancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study A. Ciprani, Rome/IT
15:05-15:10	Second-Generation Dual-Layer Spectral CT: Impact of Virtual Monoenergetic Imaging on Image Quality G. B. Zamarra, Rome/IT
15:10-15:15	Split-bolus CT with CNN-based denoising for low-dose oncologic Imaging O. Povshedna, Kyiv/UA
15:15-15:20	Could Contrast-Enhanced Ultrasound (CEUS) serve as a noninvasive diagnostic tool to distinguish degenerative thyroid nodules (DTN) from papillary thyroid carcinoma (PTC)? A preliminary study R. Samanskis, Riga/LV
15:20-15:25	AI-Derived Visceral Fat from Routine Baseline CT Scans Provides Independent and Incremental Prognostic Information Beyond Established Clinical Risk Factors in PDAC – Results from the Multicenter METAPAC Cohort F. Herr, Munich/DE
15:25-15:40	Discussion

14:40-15:40 **Scientific Session 4: AI, Miscellaneous** (Foyer)

Moderators: M. Mayerhöfer, New York/US, J. Rübenthaler, Munich/DE

Don't miss key insights from our colleagues on Artificial Intelligence and further relevant topics. Dive into the latest research and discover new updates in the field. A syllabus of all presented abstracts will be available through the ESOI website.

14:40-14:45	Prospective Evaluation of WB-DWI MRI for Detection of Hepatic and Extrahepatic Disease in Neuroendocrine Tumors: Comparison with SSTR-PET/CT I. Indzhiev, Munich/DE
-------------	---

14:45-14:50	Optimized Threshold-Based Segmentation Approach for Response Assessment in [¹⁸F]SiTATE PET/CT Response Assessment in GEP-NET Under Somatostatin Analogs M. Fauter, Munich/DE
14:50-14:55	Quantitative Magnetic Resonance Imaging for the Differentiation of Soft Tissue Tumors N. Wunderlich, Dresden/DE
14:55-15:00	Specialist or Generalist – Is Task-Specific nnU-Net better than Foundation Models for Bone Metastasis Segmentation on CT? M. Radziņa, Riga/LV
15:00-15:05	Sequential Forward Selection with radiomics features from susceptibility-weighted MRI for classification of adult-type diffuse glioma A. M. Scherer, Heidelberg/DE
15:05-15:10	Comparison of the Diagnostic Performance of the Malignancy Score of Lung Nodules Calculated by an AI-based Software between CT Data Sets from Germany and France J. Minuth, Heidelberg/DE
15:10-15:15	Human-AI Interaction in Prostate MRI Interpretation in a cohort of 369 patients: Effect of reading style and reading personality in experienced radiologists D. Bonekamp, Heidelberg/DE
15:15-15:20	Natural evolution of cystic neuroendocrine tumors of pancreas F. Omboni, Verona/IT
15:20-15:25	FocalLesionDetector: AI-based automated focal lesion quantification from whole-body MRI in multiple myeloma patients M. Wennmann, Heidelberg/DE
15:25-15:40	Discussion
15:40-16:15	Coffee Break & Industry Sponsored Quiz ☕

16:15-17:15	Neuroendocrine Tumors
	Moderators: D. Caruso, Rome/IT, G. Zamboni, Verona/IT
16:15-16:30	Neuroendocrine Tumors: How to Establish the Correct Clinical Approach
	F. Panzuto, Rome/IT
16:30-16:45	Optimizing the Patient Journey Through Multidisciplinary Care In Referral Centers
	N. Fazio, Milan/IT
16:45-17:00	Role of Imaging in Clinical Trials
	M. Knopp, Cincinnati/US
17:00-17:15	Discussion

17:15-18:00 **Interactive Workshops**

Highly interactive environment in smaller groups with live discussion. Participants are free to decide which workshop to attend.

Workshop 1: MRI Characterization of Ovarian Masses (Auditorium)

L. Fournier, Paris/FR

E. Vasiliu, Bucharest/RO

Workshop 2: Bone Metastasis & Their Mimics (Room K1)

S. Gitto, Milan/IT

S. Kaur, Oswestry/UK

Workshop 3: Imaging in Hematologic Malignancies (Room K2)

D. Leithner, New York/US

M. Mayerhöfer, New York/US

Workshop 4: Patient Communication for Radiologists (Foyer)

D. Carrié, Toulouse/FR

M. Zerunian, Rome/IT

Workshop EUCAIM: The Cancer Image Europe Infrastructure: Leveraging Cancer Imaging Data for Research and Innovation

S. Flor, Valencia/ES

H. Leisz, Heidelberg/DE

Saturday, October 31, 2026

08:30-09:15 Interactive Workshops

Highly interactive environment in smaller groups with live discussion. Participants are free to decide which workshop to attend.

Workshop 5: Primary Liver Malignancies: Imaging for Detection and Treatment (Auditorium)

S. Kale, Bengaluru/IN

M. Radziņa, Riga/LV

G. Zamboni, Verona/IT

Workshop 6: Challenges in Head & Neck Imaging (Room K1)

E. Vassallo, Msida/MT

A. Venkatasamy, Paris/FR

Workshop 7: Prostate Cancer: From PI-RADS to Individualized Care (Room K2)

T. Boellaard, Amsterdam/NL

G. Cappello, Turin/IT

Workshop 8: Communication of Scientific Results: How to present yourself (Foyer)

A. Borgheresi, Ancona/IT

G. Sargsyan, Yerevan/AM

09:15-09:25 Break

09:25-09:45 The Future of Oncologic Imaging

R. Beets-Tan, Amsterdam/NL

09:45-10:45 Innovations in Cancer Screening

Moderators: A. R. Larici, Rome/IT, P. Rudenko, Valencia/ES

09:45-10:00 Breast

P. Clauser, Vienna/AT

10:00-10:15 Prostate

A. Vargas, New York/US

10:15-10:30 From Insights to Impact: Advancing Lung Cancer Screening in Europe

E. Nischwitz, Heidelberg/DE

10:30-10:45 Discussion

10:45-11:15	Coffee Break ☕
-------------	----------------

11:15-12:15	Gynecological Oncology MDT
-------------	-----------------------------------

Witness a real-world multidisciplinary team in action. This session is designed as a lively, collaborative debate to show how different specialties align on complex cases. You will hear expert perspectives and interactive discussion amongst gynaecological surgery, gynaecological oncology and radiation therapy.

E. Meixner, Heidelberg/DE

T. Mokry, Heidelberg/DE

F. Stroisch, Heidelberg/DE

L. Sych, Heidelberg/DE

12:15-12:25	Break 🕒
-------------	---------

12:25-13:25	Dark side of the Treatment: Imaging Toxicities of Contemporary Cancer Treatment
-------------	--

Moderators: S. Shaikh, Hyderabad/IN, I. Trofimenko, Lisbon/PT, S. Zschäbitz, Heidelberg/DE

12:25-12:40	Brain toxicities
-------------	-------------------------

I. Trofimenko, Lisbon/PT

12:40-12:55	Thoracic Toxicities
-------------	----------------------------

W. Kunz, Munich/DE

12:55-13:10	Abdominal Toxicities
-------------	-----------------------------

D. Lambregts, Amsterdam/NL

13:10-13:25	System Manifestations of Cancer Therapy
-------------	--

K. Kenigsberg, Haifa/IL

13:25-13:40	Closing + Awarding Session
-------------	----------------------------

Disclosure Statements

It is the policy of the ESOI to ensure balance, independence, objectivity, and scientific rigour in the congress programme. Knowledge of possible relationships with sponsors of any kind is mandatory in order to reinforce the educational and scientific message and to relieve any suspicion of bias.

Any potential conflict of interest involving the organising committee will be made known through our onsite printed programme brochure so that the audience may form their own judgements about the presentation with a full disclosure of the facts. It is for the audience to determine whether the presenter's external interest may reflect a possible bias in either the work carried out or the conclusions presented.